Central Nervous System Neoplasms
"Central Nervous System Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.
| Descriptor ID |
D016543
|
| MeSH Number(s) |
C04.588.614.250 C10.551.240
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Central Nervous System Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Central Nervous System Neoplasms".
This graph shows the total number of publications written about "Central Nervous System Neoplasms" by people in this website by year, and whether "Central Nervous System Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 3 | 0 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 2 | 0 | 2 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 4 | 0 | 4 |
| 2014 | 3 | 0 | 3 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 2 | 3 |
| 2017 | 2 | 1 | 3 |
| 2018 | 3 | 1 | 4 |
| 2019 | 4 | 0 | 4 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 4 | 0 | 4 |
| 2023 | 3 | 0 | 3 |
| 2024 | 3 | 0 | 3 |
| 2025 | 5 | 0 | 5 |
| 2026 | 7 | 0 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Central Nervous System Neoplasms" by people in Profiles.
-
The evolution of RTOG and NRG Oncology CNS tumors clinical trials. J Neurooncol. 2026 Sep 15; 179(2).
-
Infant Embryonal CNS Tumors: Molecular Insights and Treatment Considerations for Contemporary Pediatric Neuro-Oncology. Pediatr Blood Cancer. 2026 Nov; 73(11):e70624.
-
Central Nervous System Neuroblastoma, FOXR2-Activated: A Pooled Analysis of Published Clinical Outcomes. Pediatr Blood Cancer. 2026 Sep; 73(9):e70445.
-
Adding induction intrathecal cytarabine in newly diagnosed CNS2 B-acute lymphoblastic leukemia does not improve outcomes. Blood Adv. 2026 06 23; 10(12):4184-4192.
-
Diagnosis and Management of Multiple Myeloma With Central Nervous System Involvement. J Natl Compr Canc Netw. 2026 Mar 09; 24(5).
-
Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma. Neuro Oncol. 2026 Feb 01; 28(2):371-382.
-
A Report from the Inaugural Society of NeuroInterventional Surgery Neurointerventional Oncology Summit. AJNR Am J Neuroradiol. 2026 01 05; 47(1):1-8.
-
Uncertainty-aware ensemble of foundation models differentiates glioblastoma from its mimics. Nat Commun. 2025 Sep 29; 16(1):8341.
-
Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement. Blood Adv. 2025 Aug 26; 9(16):4081-4089.
-
Analytical Validation and Clinical Sensitivity of the Belay Summit Assay for the Detection of DNA Variants in Cerebrospinal Fluid of Primary and Metastatic Central Nervous System Cancer. J Mol Diagn. 2025 Jul; 27(7):615-629.